Efficacy of 12-months oral itraconazole versus 6-months oral itraconazole to prevent relapses of chronic pulmonary aspergillosis: an open-label, randomised controlled trial in India (vol 22, pg 1052, 2022)

被引：0

|

作者：

Sehgal, I. S.

Dhooria, S.

Muthu, V

机构：

来源：

LANCET INFECTIOUS DISEASES | 2023年 / 23卷 / 02期

关键词：

D O I：

10.1016/S1473-3099(22)00802-7

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

引用

收藏

页码：E47 / E47

页数：1

相关论文

共 9 条

[1] Efficacy of 12-months oral itraconazole versus 6-months oral itraconazole to prevent relapses of chronic pulmonary aspergillosis: an open-label, randomised controlled trial in India
Sehgal, Inderpaul S.
Dhooria, Sahajal
Muthu, Valliappan
Prasad, Kuruswamy T.
Aggarwal, Ashutosh N.
Chakrabarti, Arunaloke
Choudhary, Hansraj
Garg, Mandeep
Agarwal, Ritesh
LANCET INFECTIOUS DISEASES, 2022, 22 (07): : 1052 - 1061
[2] Efficacy and tolerance of oral versus parenteral cyanocobalamin supplement in hypocobalaminaemic dogs with chronic enteropathy: a controlled randomised open-label trial
Dor, C.
Nixon, S.
Schmitz, S. Salavati
Bazelle, J.
Cerna, P.
Kilpatrick, S.
Harvey, N. D.
Dunning, M.
JOURNAL OF SMALL ANIMAL PRACTICE, 2024, 65 (05) : 317 - 328
[3] Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label randomised controlled ORAL Surveillance trial (vol 81, pg 1491, 2022)
Balanescu, A. R.
Citera, G.
Pascual-Ramos, V
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (10) : E219 - E219
[4] Complementary feeding at 4 versus 6 months of age for preterm infants born at less than 34 weeks of gestation: a randomised, open-label, multicentre trial (vol 5, pg e501, 2017)
Gupta, S.
Agarwal, R.
Aggarwal, K. C.
LANCET GLOBAL HEALTH, 2018, 6 (05): : E499 - E499
[5] Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients with pulmonary tuberculosis in India (RATIONS): a field-based, open-label, cluster-randomised, controlled trial (vol 402, pg 627, 2023)
Rugo, Hope S.
Bardia, Aditya
Tolaney, Sara
LANCET, 2024, 404 (10450): : 340 - 340
[6] Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial (vol 7, pg 528, 2019)
Pieber, T. R.
Bode, B.
Mertens, A.
LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (09): : E21 - E21
[7] Ferric carboxymaltose infusion versus oral iron supplementation for preoperative iron deficiency anaemia in patients with colorectal cancer (FIT): a multicentre, open-label, randomised, controlled trial (vol 10, pg e250, 2023)
Talboom, K.
Borstlap, W. A. A.
Roodbeen, S. X.
LANCET HAEMATOLOGY, 2023, 10 (06): : E399 - E399
[8] Efficacy of RTS,S/AS01 E malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5-17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial (vol 22, pg 1329, 2022)
Samuels, A. M.
Ansong, D.
Kariuki, S. K.
LANCET INFECTIOUS DISEASES, 2022, 22 (11): : E310 - E310
[9] Safety and effectiveness of intravenous iron sucrose versus standard oral iron therapy in pregnant women with moderate-to-severe anaemia in India: a multicentre, open-label, phase 3, randomised, controlled trial (vol 7, e1706, 2019)
Neogi, S. B.
Devasenapathy, N.
Singh, R.
LANCET GLOBAL HEALTH, 2020, 8 (12): : E1472 - E1472